Non-Hodgkin Lymphoma — Expanded Access Programs
Overview
Right2Hope maintains a directory of 45 expanded access programs, clinical trials, and compassionate use pathways listed for Non-Hodgkin Lymphoma. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with non-hodgkin lymphoma programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 12 programs are currently active or recruiting, with the remaining 33 in other lifecycle stages. Sponsors actively running programs in this area include Eli Lilly and Company, Genmab, M.D. Anderson Cancer Center, National Cancer Institute (NCI), New York Medical College, and others.
By recruiting status
Snapshot of where every Non-Hodgkin Lymphoma program currently sits in its lifecycle.
- Active / Recruiting12
- Inactive33
Top sponsors
Organisations running the most Non-Hodgkin Lymphoma programs in the directory.
- Eli Lilly and Company2 programs
- Genmab2 programs
- M.D. Anderson Cancer Center2 programs
- National Cancer Institute (NCI)2 programs
- New York Medical College2 programs
- Thomas Jefferson University2 programs
- University of Texas Southwestern Medical Center2 programs
- Abramson Cancer Center at Penn Medicine1 program
- Acerta Pharma BV1 program
- Artiva Biotherapeutics, Inc.1 program
Non-Hodgkin Lymphoma programs (45)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Study on the Long-Term Safety of Pirtobrutinib (LY3527727) — Eli Lilly and Company
- Study on WTX-330 for Adults with Advanced or Metastatic Solid Tumors or Lymphoma — Werewolf Therapeutics, Inc.
- Study on Pirtobrutinib for Patients with Previously Treated Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma — Eli Lilly and Company
- Study on Carmustine With and Without Ethanol for Lymphoma Patients — VIVUS LLC
- Study on Adding Ruxolitinib to Pembrolizumab for Treating Relapsed or Resistant Hodgkin and Non-Hodgkin Lymphomas — Seda S. Tolu
- Cord Blood Transplantation for Children and Young Adults with Blood Cancer — Memorial Sloan Kettering Cancer Center
- Study on Epcoritamab, Zanubrutinib, and Rituximab for Treating Relapsed or Refractory Follicular Lymphoma — Reid Merryman, MD
- Study on Using Intrathecal Rituximab with Standard Treatment to Prevent CNS Relapse in CD20+ Non-Hodgkin Lymphoma — Tahir Latif
- Study on Using Mozobil for Stem Cell Transplantation — Thomas Jefferson University
- Study on the Safety and Effectiveness of KRT-232 with Acalabrutinib for Treating Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia — Kartos Therapeutics, Inc.
- Study on Acalabrutinib Alone or Combined with Other Treatments for B-cell Non-Hodgkin Lymphoma — Acerta Pharma BV
- Study on IOMAB-ACT and CAR-T Cell Therapy for Patients with Difficult or Returning Diffuse Large B-cell Lymphoma — University of Texas Southwestern Medical Center
- Study on Using Radiation Therapy After Partial Response to CAR-T in Relapsed or Refractory Non-Hodgkin Lymphoma — University of Texas Southwestern Medical Center
- Study on KB-0742 for Patients with Relapsed or Hard-to-Treat Solid Tumors or Non-Hodgkin Lymphoma — Kronos Bio
- Study on BGB-16673 for Patients with B-Cell Blood Cancers — BeiGene
- A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma — Genmab
- Study on the Safety and Effectiveness of CTX112 for Treating Difficult or Returning B-Cell Cancers — CRISPR Therapeutics AG
- Study on Mosunetuzumab and Polatuzumab Vedotin Compared to Rituximab with Gemcitabine and Oxaliplatin for Relapsed or Hard-to-Treat Aggressive B-Cell Non-Hodgkin's Lymphoma — Hoffmann-La Roche
- Study on the Safety, Effectiveness, and Behavior of Mosunetuzumab Alone in Patients with Certain B-Cell Cancers — Genentech, Inc.
- A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma — Cho Pharma Inc.
- Study on Epcoritamab with Other Cancer Treatments for Adults with Non-Hodgkin Lymphoma — Genmab
- Study on AB-101 Alone and with Immunotherapy for Patients with Relapsed or Hard-to-Treat B-Cell Non-Hodgkin Lymphoma — Artiva Biotherapeutics, Inc.
- Study on Stem Cell Transplantation for Blood Disorders Using Special Cell Depletion — Mitchell Cairo
- Study on Using a Patient's Own Stem Cells for Treating Lymphoma — Masonic Cancer Center, University of Minnesota
- Study on Chemoradiotherapy with Targeted Immunotherapy for Pediatric Lymphoma — New York Medical College
- Study on Cord Blood Transplant with Chemotherapy and Radiation for Treating High-Risk Blood Diseases — Fred Hutchinson Cancer Center
- Study on Cytokine-Treated Veto Cells for Patients with Blood Cancers After Stem Cell Transplant — M.D. Anderson Cancer Center
- Access to AVM0703 for Patients with Solid Tumors and Blood Cancers — AVM Biotechnology Inc
- Study on Golcadomide and Nivolumab for Non-Hodgkin Lymphoma After CAR-T Therapy — Natalie Galanina
- Study on Isatuximab During Stem Cell Collection and Transplant for Patients with Multiple Myeloma and Lymphoma — Divaya Bhutani
- Study on Methionine PET/CT Imaging for Cancer Patients — St. Jude Children's Research Hospital
- Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma — University of Washington
- NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma — Nektar Therapeutics
- Study on Obinutuzumab and ICE Chemotherapy for Difficult or Returning CD20+ Non-Hodgkin Lymphoma — New York Medical College
- Phase II Study of Pirtobrutinib and Venetoclax for Patients with Relapsed or Refractory Mantle Cell Lymphoma (MCL) — M.D. Anderson Cancer Center
- Phase 1/2 Study of IPH6501 in Patients with Relapsed or Hard-to-Treat B-Cell Non-Hodgkin Lymphoma — Innate Pharma
- Study on PRO1160 for Treating Advanced Solid and Liquid Tumors — ProfoundBio US Co.
- Study on RADVAX™ for Relapsed or Hard-to-Treat Non-Hodgkin Lymphoma: Phase II Trial of Pembrolizumab and Low-Dose Radiotherapy — Abramson Cancer Center at Penn Medicine
- Study on Reduced-Intensity Conditioning to Lower Treatment-Related Deaths in Patients Undergoing Stem Cell Transplant — Thomas Jefferson University
- Study on SB-4826 for Adults with Advanced Solid Tumors or Non-Hodgkin Lymphomas — University of California, San Diego
- Study of VIP152, Venetoclax, and Prednisone (VVIP) in Treating Difficult or Returning Blood Cancers — National Cancer Institute (NCI)
- Study on CCS1477 for Blood Cancers — CellCentric Ltd.
- Study on T-Cell Therapy (EB103) for Adults with Difficult or Returning B-Cell Non-Hodgkin's Lymphoma — Estrella Biopharma, Inc.
- Study on Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) for Treating B-cell Lymphoma That Has Returned or Not Improved — National Cancer Institute (NCI)
- Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation — University of Michigan Rogel Cancer Center
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Non-Hodgkin Lymphoma to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.